NICE published a draft Diagnostic guideline on the Reveal LINQ monitor.
In the draft guideline, published in January 2020, NICE provided the following recommendations:
- Reveal LINQ is recommended for routine adoption to help to detect atrial fibrillation after cryptogenic stroke only if:
- Non-invasive electrocardiogram (ECG) monitoring has been done, and
- No other cause for the stroke has been found
- Clinicians should consider if disabled people may need support from a carer to help set up the MyCareLink Patient Monitor, to ensure data from Reveal LINQ is transmitted for review
- There is not enough evidence to recommend the routine adoption of BioMonitor 2-AF (or its successor device BIOMONITOR III) or Confirm Rx to help to detect atrial fibrillation after cryptogenic stroke. Further research is recommended to assess the diagnostic yield (a measure of how many people with atrial fibrillation are diagnosed) of these devices for atrial fibrillation when used in people who have had a cryptogenic stroke
The expected publication date of the final guideline is 27 May 2020.
See the full details here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.